| Literature DB >> 35300942 |
Ching-Feng Wu1, Jui-Ying Fu2, Ying-Sheng Li1, Chi-Tsung Wen1, Yung-Liang Wan3, Yun-Hen Liu1, Ming-Ju Hsieh1, Ching-Yang Wu4.
Abstract
BACKGROUND: Image characteristics of tumor, including tumor size and component are crucial for patients' survival. Patients who presented with ground glass opacity (GGO) was found less risk of intrapulmonary lymph node metastases and good survival. However, it is difficult to get tissue prove for small GGO lesion preoperatively because of its tiny size and the accuracy of intraoperation frozen section. Some patients received another operation for anatomic resection after malignancy has been confirmed and others refused reoperation and only received wedge resection. The aim of this study was tried to compare the treatment result between anatomic and wedge resection for non small cell lung cancer patients who present as small ground glass opacity (GGO) predominant lesion in pre-operation CT.Entities:
Keywords: Ground glass opacity; Non-small cell lung cancer; Tumor size
Mesh:
Year: 2020 PMID: 35300942 PMCID: PMC9068530 DOI: 10.1016/j.bj.2020.11.001
Source DB: PubMed Journal: Biomed J ISSN: 2319-4170 Impact factor: 7.892
Fig. 1Inclusion and exclusion criteria.
Clinical characteristics.
| Variables (Mean ± SD)/Mean (%) | Group A = 37 | Group B = 9 | |
|---|---|---|---|
| Age | 58.8 ± 10.8 | 59.9 ± 9.9 | 0.89 |
| Gender Female | 24 (64.9) | 7 (70.0) | 0.69 |
| Body height | 158.8 ± 8.2 | 159.4 ± 9.9 | 0.95 |
| Body weight | 59.5 ± 10.5 | 62.6 ± 9.4 | 0.55 |
| FEV 1 | 2.1 ± 0.5 | 2.1 ± 0.6 | 0.81 |
| FVC | 2.7 ± 0.6 | 2.5 ± 0.7 | 0.65 |
| FEV 1/FVC | 0.8 ± 0.1 | 0.8 ± 0.03 | 0.08 |
| CT finding Tumor size | 1.3 ± 0.4 | 1.1 ± 0.5 | 0.36 |
| CT tumor component | 0.69 | ||
| Pure GGO | 24 (64.9) | 7 (77.8) | |
| GGO predominant | 13 (35.2) | 2 (22.2) | |
| GGO location | 0.08 | ||
| Peripheral | 27 | 9 | |
| Central | 10 | 0 | |
| Co-morbidities | 0.38 | ||
| Cardiovascular | 3 (8.1) | 0 | 0.48 |
| Pulmonary | 2 (5.4) | 0 | 0.62 |
| Gastrointestinal | 1 (2.7) | 0 | – |
| Renal | 0 | 0 | 0.62 |
| Wound | 1 (2.7) | 0 | |
| VATS/Thoracotomy | 0.62 | ||
| VATS | 36 (97.3) | 9 (100) | |
| Thoracotomy | 1 (2.7) | 0 | |
| Total staples | 9.4 ± 3.5 | 5.4 ± 1.6 | 0.01 |
| Blood Loss (ml) | 49.9 ± 47.2 | 10.00 ± 0 | 0.02 |
| Operation time (min) | 205.8 ± 57.7 | 245.4 ± 62.6 | 0.16 |
| Post OP days | 6.7 ± 4.9 | 5.4 ± 0.9 | 0.82 |
| Total hospital days | 10.0 ± 6.4 | 9.0 ± 5.7 | 0.48 |
| Median follow up period | 1303.3 ± 455.7 | 1303.2 ± 314.6 | 0.97 |
Pathologic characteristics.
| Pathologic characteristics | Group A = 37 | Group B = 9 | |
|---|---|---|---|
| Cell type | – | ||
| Adenocarcinoma | 37 (100) | 9 (100.00) | |
| Predominant component | 0.23 | ||
| Bronchioalveolar | 7 (18.9) | 1 (11.1) | |
| Acinar | 14 (37.8) | 7 (77.8) | |
| Papillary | 7 (18.9) | 1 (11.1) | |
| Micropapillary | 7 (18.9) | 0 (0) | |
| Solid | 2 (5.4) | 0 (0) | |
| Pathologic tumor size | 1.3 ± 0.5 | 1.1 ± 0.4 | 0.58 |
| Visceral pleural invasion | 1 (2.70) | 0 | 0.62 |
| Angiolymphatic invasion | 1 (2.7) | 1 (11.1) | 0.36 |
| Grade | 0.07 | ||
| Well differentiated | 32 (86.5) | 9 (100.00) | |
| Moderately differentiated | 5 (13.5) | 0 (0) | |
| Lymph node status | |||
| Non-metastastic LN No. | 18.5 ± 0.70 | 9.1 ± 7.9 | 0.01 |
| Total LN No. | 18.6 ± 8.7 | 9.1 ± 7.9 | 0.01 |
| Metastatic N1 LN No. | 0.02 ± 0.2 | 0 ± 0 | 0.69 |
| Non-metastatic N1 LN No. | 5.1 ± 3.1 | 0.8 ± 1.0 | 0.0002 |
| Metastatic N2 LN No. | 0.03 ± 0.2 | 0 ± 0 | 0.69 |
| Non-metastatic N2 LN No. | 13.2 ± 7.3 | 8.4 ± 7.2 | 0.10 |
| Pathologic stage | 0.71 | ||
| stage 1a | 32 (86.5) | 9 (100) | |
| stage 1b | 1 (2.70) | – | |
| stage 2a | – | – | |
| stage 2b | 2 (5.4) | – | |
| stage 3a | 2 (5.4) | – | |
Fig. 2Disease free survival (A) Patient presented as GGO predominant lesion less than 2 cm (Clinical 1a) [ Lobectomy (37) versus wedge resection (9)]. (B) Pathologic 1a patients who presented as GGO predominant lesion less than 2 cm [ Lobectomy (31) versus wedge resection (9)] 6 patients of anatomic resection group were excluded. 5 patients were excluded due to pathologic stage greater than Ia, while one was excluded after he died due to nasopharyngeal carcinoma progression. Due to no disease relapse that correlated to lung cancer, both groups show identical disease free survival and no p value was obtained.
Fig. 3Overall survival. (A) Patient presented as GGO predominant lesion less than 2 cm (Clinical 1a). [ Lobectomy (37) versus wedge resection (9)]. (B) Pathologic 1a patients who presented as GGO predominant lesion less than 2 cm [ Lobectomy (32) versus wedge resection (9)] 6 patients of anatomic resection group were excluded. 5 patients were excluded due to pathologic stage greater 1a.